About this Journal Submit a Manuscript Table of Contents
ISRN Oncology
Volume 2013 (2013), Article ID 863909, 5 pages
http://dx.doi.org/10.1155/2013/863909
Clinical Study

Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

1Department of Hematology, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
2Division of Pathology, The Cancer Institute, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
3Pathology Project for Molecular Targets, The Cancer Institute, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
4Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan

Received 11 February 2013; Accepted 28 February 2013

Academic Editors: W. Kildal and Y.-Y. Liu

Copyright © 2013 Masahiro Yokoyama et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Masahiro Yokoyama, Yasuhito Terui, Kengo Takeuchi, et al., “Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan,” ISRN Oncology, vol. 2013, Article ID 863909, 5 pages, 2013. doi:10.1155/2013/863909